| Tanyatta Lane-king, NP | |
|
3 Richland Medical Park Dr Ste 310, Columbia, SC 29203-6862 | |
| (803) 434-8323 | |
| (803) 434-8326 |
| Full Name | Tanyatta Lane-king |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 3 Richland Medical Park Dr Ste 310, Columbia, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013490911 | NPI | - | NPPES |
| NP5549 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 22205 (South Carolina) | Primary |
| Entity Name | Apogee Medical Group South Carolina |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619028545 PECOS PAC ID: 8921193020 Enrollment ID: O20071004000474 |
News Archive
AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.
A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.
Most directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The Department of Health and Human Services (HHS) has announced that $25 million is available to hospitals and other health care facilities via a competitive emergency care grant program focused on hospital surge capacity, emergency care system capability, and community and hospital preparedness for public health emergencies.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 3 days ago
| Entity Name | Cogent Healthcare Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609827823 PECOS PAC ID: 2961483607 Enrollment ID: O20151015001850 |
News Archive
AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.
A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.
Most directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The Department of Health and Human Services (HHS) has announced that $25 million is available to hospitals and other health care facilities via a competitive emergency care grant program focused on hospital surge capacity, emergency care system capability, and community and hospital preparedness for public health emergencies.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 3 days ago
| Entity Name | Southeastern Hospitalist Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003280108 PECOS PAC ID: 3476855420 Enrollment ID: O20160125000378 |
News Archive
AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.
A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.
Most directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The Department of Health and Human Services (HHS) has announced that $25 million is available to hospitals and other health care facilities via a competitive emergency care grant program focused on hospital surge capacity, emergency care system capability, and community and hospital preparedness for public health emergencies.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 3 days ago
| Entity Name | Prisma Health Medical Group-midlands |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275988321 PECOS PAC ID: 5991099707 Enrollment ID: O20160802001226 |
News Archive
AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.
A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.
Most directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The Department of Health and Human Services (HHS) has announced that $25 million is available to hospitals and other health care facilities via a competitive emergency care grant program focused on hospital surge capacity, emergency care system capability, and community and hospital preparedness for public health emergencies.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 3 days ago
| Entity Name | Musc Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841878006 PECOS PAC ID: 6507260668 Enrollment ID: O20210811002388 |
News Archive
AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.
A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.
Most directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The Department of Health and Human Services (HHS) has announced that $25 million is available to hospitals and other health care facilities via a competitive emergency care grant program focused on hospital surge capacity, emergency care system capability, and community and hospital preparedness for public health emergencies.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tanyatta Lane-king, NP Po Box 935722, Atlanta, GA 31193-5722 Ph: (843) 792-2300 | Tanyatta Lane-king, NP 3 Richland Medical Park Dr Ste 310, Columbia, SC 29203-6862 Ph: (803) 434-8323 |
News Archive
AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.
A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue publishedthis monthin American Journal of Obstetrics and Gynecology.
Most directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The Department of Health and Human Services (HHS) has announced that $25 million is available to hospitals and other health care facilities via a competitive emergency care grant program focused on hospital surge capacity, emergency care system capability, and community and hospital preparedness for public health emergencies.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 3 days ago
Mr. Joseph Crawford Iii, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Richland Medical Park Dr Ste 300, Columbia, SC 29203 Phone: 803-256-6511 | |
Richard Hall Iii, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Richland Medical Park Dr Ste 100, Columbia, SC 29203 Phone: 803-434-6095 Fax: 803-758-0120 | |
Latonya Brailsford, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4605 Monticello Rd Ste 2, Columbia, SC 29203 Phone: 803-753-5590 Fax: 803-753-5592 | |
Laketa D Riley, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Doctor Cir, Columbia, SC 29203 Phone: 800-491-0909 | |
Jenny O'neill, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 200 Arbor Lake Dr, Suite 120, Columbia, SC 29223 Phone: 803-457-8125 Fax: 803-457-8129 | |
Sarah Elizabeth Wilson, PNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9 Richland Medical Park Dr Ste 420, Columbia, SC 29203 Phone: 803-434-3950 Fax: 803-434-3496 | |
Miss Karen Mccain, NURSE PRACTITONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Doctor Cir, Columbia, SC 29203 Phone: 800-491-0909 |